Tags

Type your tag names separated by a space and hit enter

Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Pediatr Infect Dis J. 2015 Dec; 34(12):e298-307.PI

Abstract

BACKGROUND

We evaluated safety, immunogenicity and antibody persistence of meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine (MenACWY-TT) booster vaccination 4 years after priming of toddlers.

METHODS

This phase III, open-label, controlled study in Finland (NCT00955682) enrolled children previously randomized (3:1) at 12-23 months (NCT00474266) to receive 1 dose of MenACWY-TT or MenC conjugate vaccine (MenC-CRM197). Serum bactericidal antibody titers using rabbit (rSBA, cut-off 1:8) and human complement (hSBA, cut-off 1:8) were assessed at year 3 and 4 after priming and 1 month and 1 year after administration of a booster dose of the same vaccine given for primary vaccination. Reactogenicity and safety were assessed, and vaccination-related serious adverse events were recorded from the time of primary vaccination.

RESULTS

Before booster (year 4), 74.1%, 40.4%, 49.3% and 58.2% of MenACWY-TT-recipients retained rSBA titers ≥1:8 for serogroups A, C, W and Y, respectively; 28.8%, 73.2%, 80.6% and 65.4% retained hSBA ≥1:8. Percentages for the MenC-CRM group were 35.6% (rSBA-MenC) and 46.9% (hSBA-MenC). After MenACWY-TT booster, ≥99.5% had rSBA ≥1:8 and hSBA ≥1:8 for each serogroup. After MenC-CRM197 booster, all children had rSBA-MenC ≥1:8 and hSBA-MenC ≥1:8. At year 5, percentages above the cut-off were ≥97.4% (rSBA) and ≥95.5% (hSBA) in MenACWY-TT-vaccinees for each serogroup. The MenACWY-TT booster dose had a clinically acceptable safety profile. No vaccine-related serious adverse events were reported.

CONCLUSION

There was evidence of antibody persistence 4 years after toddlers were primed with MenACWY-TT. Booster vaccination induced robust immune responses for all serogroups with an acceptable safety profile.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Vesikari T
From the *Vaccine Research Center, University of Tampere Medical School, Tampere, Finland; † Clinical R&D, GSK Vaccines, Wavre, Belgium; and ‡Vaccines Discovery & Development, GSK Vaccines, King of Prussia, Pennsylvania.
Forsten A
No affiliation info available
Bianco V
No affiliation info available
Van der Wielen M
No affiliation info available
Miller JM
No affiliation info available

MeSH

Antibodies, BacterialChild, PreschoolFemaleHumansImmunization, SecondaryMaleMeningococcal InfectionsMeningococcal VaccinesVaccines, Conjugate

Pub Type(s)

Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

26780033

Clinical Trial Links

Clinical trial which this article describes
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Citation

Vesikari, Timo, et al. "Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared With Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines." The Pediatric Infectious Disease Journal, vol. 34, no. 12, 2015, pp. e298-307.
Vesikari T, Forsten A, Bianco V, et al. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines. Pediatr Infect Dis J. 2015;34(12):e298-307.
Vesikari, T., Forsten, A., Bianco, V., Van der Wielen, M., & Miller, J. M. (2015). Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines. The Pediatric Infectious Disease Journal, 34(12), e298-307. https://doi.org/10.1097/INF.0000000000000897
Vesikari T, et al. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared With Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines. Pediatr Infect Dis J. 2015;34(12):e298-307. PubMed PMID: 26780033.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines. AU - Vesikari,Timo, AU - Forsten,Aino, AU - Bianco,Veronique, AU - Van der Wielen,Marie, AU - Miller,Jacqueline M, PY - 2016/1/19/entrez PY - 2016/1/19/pubmed PY - 2016/10/19/medline SP - e298 EP - 307 JF - The Pediatric infectious disease journal JO - Pediatr Infect Dis J VL - 34 IS - 12 N2 - BACKGROUND: We evaluated safety, immunogenicity and antibody persistence of meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine (MenACWY-TT) booster vaccination 4 years after priming of toddlers. METHODS: This phase III, open-label, controlled study in Finland (NCT00955682) enrolled children previously randomized (3:1) at 12-23 months (NCT00474266) to receive 1 dose of MenACWY-TT or MenC conjugate vaccine (MenC-CRM197). Serum bactericidal antibody titers using rabbit (rSBA, cut-off 1:8) and human complement (hSBA, cut-off 1:8) were assessed at year 3 and 4 after priming and 1 month and 1 year after administration of a booster dose of the same vaccine given for primary vaccination. Reactogenicity and safety were assessed, and vaccination-related serious adverse events were recorded from the time of primary vaccination. RESULTS: Before booster (year 4), 74.1%, 40.4%, 49.3% and 58.2% of MenACWY-TT-recipients retained rSBA titers ≥1:8 for serogroups A, C, W and Y, respectively; 28.8%, 73.2%, 80.6% and 65.4% retained hSBA ≥1:8. Percentages for the MenC-CRM group were 35.6% (rSBA-MenC) and 46.9% (hSBA-MenC). After MenACWY-TT booster, ≥99.5% had rSBA ≥1:8 and hSBA ≥1:8 for each serogroup. After MenC-CRM197 booster, all children had rSBA-MenC ≥1:8 and hSBA-MenC ≥1:8. At year 5, percentages above the cut-off were ≥97.4% (rSBA) and ≥95.5% (hSBA) in MenACWY-TT-vaccinees for each serogroup. The MenACWY-TT booster dose had a clinically acceptable safety profile. No vaccine-related serious adverse events were reported. CONCLUSION: There was evidence of antibody persistence 4 years after toddlers were primed with MenACWY-TT. Booster vaccination induced robust immune responses for all serogroups with an acceptable safety profile. SN - 1532-0987 UR - https://www.unboundmedicine.com/medline/citation/26780033/Immunogenicity_Safety_and_Antibody_Persistence_of_a_Booster_Dose_of_Quadrivalent_Meningococcal_ACWY_tetanus_Toxoid_Conjugate_Vaccine_Compared_with_Monovalent_Meningococcal_Serogroup_C_Vaccine_Administered_Four_Years_After_Primary_Vaccination_Using_the_Same_Vaccines_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓12 ↑1]

Related Citations

More